Jacqueline Bromberg

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Stat proteins and oncogenesis
    Jacqueline Bromberg
    Memorial Sloan-Kettering Cancer Center, 1230 York Avenue, Box 397, New York, New York 10021, USA
    J Clin Invest 109:1139-42. 2002
  2. ncbi Stat3 is required for the development of skin cancer
    Laura Pedranzini
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 114:619-22. 2004
  3. ncbi Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer
    Marjan Berishaj
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 USA
    Breast Cancer Res 9:R32. 2007
  4. ncbi Activation of STAT proteins and growth control
    J F Bromberg
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10021, USA
    Bioessays 23:161-9. 2001
  5. ncbi Stat3 mediates expression of autotaxin in breast cancer
    Janeen Azare
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 6:e27851. 2011
  6. ncbi Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3
    Kenneth Leslie
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 66:2544-52. 2006
  7. ncbi Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation
    Kenneth Leslie
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res 12:R80. 2010
  8. ncbi Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6
    Janeen Azare
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mol Cell Biol 27:4444-53. 2007
  9. ncbi Targeting the interleukin-6/Jak/stat pathway in human malignancies
    Pasquale Sansone
    Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    J Clin Oncol 30:1005-14. 2012
  10. ncbi Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells
    Laura Pedranzini
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 66:9714-21. 2006

Research Grants

  1. Role of Stat3 in Breast Cancer Tumorigenesis
    Jacqueline Bromberg; Fiscal Year: 2005
  2. Role of Stat3 in Breast Cancer Tumorigenesis
    Jacqueline F Bromberg; Fiscal Year: 2010

Collaborators

  • Katrina Podsypanina
  • Lionel Ivashkiv
  • Catherine Van Poznak
  • Ping Zhou
  • Paul H Weinreb
  • Larry Norton
  • Keren Paz
  • Katherine S Panageas
  • Monica N Fornier
  • W L Gerald
  • GEORGE ROBERT STARK
  • William Pao
  • Kenneth Leslie
  • Janeen Azare
  • Marjan Berishaj
  • Pasquale Sansone
  • Laura Pedranzini
  • Hikmat Al-Ahmadie
  • Sizhi Paul Gao
  • William Bornmann
  • Toshiyuki Sakamaki
  • Tobias N Dechow
  • Andrea Leitch
  • Jun Zhang
  • Chris Albanese
  • Joseph R Tumang
  • Jennifer Nnoli
  • David Lyden
  • Maryam Hassimi
  • Ashley Doane
  • Kevin Mark
  • Qing Chang
  • Mary Stracke
  • Agnes Viale
  • Hao Ho
  • Sizhi P Gao
  • Noriko Motoi
  • Darren Veach
  • Kevin G Mark
  • Simi Ahmed
  • Shelia M Violette
  • William D Travis
  • Bayard Clarkson
  • Geeta Devgan
  • Christopher Albanese
  • James E Darnell
  • Richard Pestell
  • Young Bae Kim
  • Raymond Comenzo
  • Tobias Dechow
  • Cynthia Lang
  • Irina Linkov
  • Udit Verma
  • Sanjit K Roy
  • Maofu Fu
  • Kongming Wu
  • Julian Hughes
  • Silvia Tininini
  • Mark D'Amico
  • Jiadi Hu
  • James Hulit
  • Stephen W Byers
  • Christy Jarrett
  • Valeria Poli
  • Jinbo Yang
  • Richard G Pestell
  • David Joyce
  • Carmela Lamberti
  • Dhananjaya V Kalvakolanu
  • Richard B Gaynor
  • Avri Ben-Ze'ev
  • Constance Y Hsia
  • Hsiou Chi Liou
  • Hsiou-Chi Liou
  • Wenzhi Tian

Detail Information

Publications18

  1. ncbi Stat proteins and oncogenesis
    Jacqueline Bromberg
    Memorial Sloan-Kettering Cancer Center, 1230 York Avenue, Box 397, New York, New York 10021, USA
    J Clin Invest 109:1139-42. 2002
  2. ncbi Stat3 is required for the development of skin cancer
    Laura Pedranzini
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 114:619-22. 2004
    ..Using the two-step model of chemically induced skin carcinogenesis, the authors demonstrated that mice deficient in Stat3 were completely resistant to skin tumor development...
  3. ncbi Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer
    Marjan Berishaj
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 USA
    Breast Cancer Res 9:R32. 2007
    ..A number of different mechanisms responsible for Stat3 activation, including abnormal activation of receptor tyrosine kinases, Src, and Janus kinases (Jaks), have been implicated in breast cancer...
  4. ncbi Activation of STAT proteins and growth control
    J F Bromberg
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10021, USA
    Bioessays 23:161-9. 2001
    ..Finally, a number of examples will be presented of how dysregulated STAT signaling may be involved in the pathogenesis of cancer...
  5. ncbi Stat3 mediates expression of autotaxin in breast cancer
    Janeen Azare
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 6:e27851. 2011
    ..These observations suggest that activated Stat3 may regulate the migration of breast cancer cells through the regulation of ATX...
  6. ncbi Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3
    Kenneth Leslie
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 66:2544-52. 2006
    ..These results suggest both a cdk-dependent and cdk-independent role for cyclin D1 in modulating transformation by different oncogenes...
  7. ncbi Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation
    Kenneth Leslie
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res 12:R80. 2010
    ..Here we examined the role of Stat3 in Ras mediated transformation...
  8. ncbi Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6
    Janeen Azare
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mol Cell Biol 27:4444-53. 2007
    ..These results demonstrate the sufficiency of constitutively activated Stat3 in mediating prostate tumorigenesis and identify novel Stat3 targets that are involved in promoting cell migration and transformation...
  9. ncbi Targeting the interleukin-6/Jak/stat pathway in human malignancies
    Pasquale Sansone
    Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA
    J Clin Oncol 30:1005-14. 2012
    ....
  10. ncbi Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells
    Laura Pedranzini
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 66:9714-21. 2006
    ..Thus, P6 is a more sensitive and specific inhibitor of JAK-STAT3 activity compared with AG490 and potently inhibited the growth of primary myeloma cells and myeloma-derived cell lines grown on BMSCs...
  11. ncbi Environment, inflammation, and cancer
    Pasquale Sansone
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Genet Dev 21:80-5. 2011
    ..This review describes some of the key molecular and cellular events demonstrating the critical role of inflammation on promoting tumorigenesis with attention on novel therapeutics and their potential clinical success...
  12. ncbi Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:223-7. 2007
    ..We conducted a pilot trial to assess the feasibility of dose-dense chemotherapy consisting of a standard regime at 10- to 11-day intervals in the adjuvant/neoadjuvant setting. A 2-day window was allowed for scheduling logistics...
  13. ncbi Inflammation and cancer: IL-6 and STAT3 complete the link
    Jacqueline Bromberg
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Cell 15:79-80. 2009
    ..Two papers by Grivennikov et al. and Bollrath et al. in this issue of Cancer Cell demonstrate the importance of the interleukin-6 family of proinflammatory cytokines and their downstream effector STAT3 in colitis-associated colon cancer...
  14. ncbi Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C
    Tobias N Dechow
    Laboratory of Molecular Cell Biology, The Rockefeller University, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:10602-7. 2004
    ..These results demonstrate a relationship between activated Stat3 and MMP-9 in breast oncogenesis...
  15. ncbi IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf
    Chris Albanese
    The Albert Einstein Cancer Center, Division of Hormone Dependent Tumor Biology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Mol Biol Cell 14:585-99. 2003
    ....
  16. ncbi The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3
    Jun Zhang
    Greenebaum Cancer Center, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 100:9342-7. 2003
    ..Because constitutively active STAT3 up-regulates antiapoptotic genes to promote tumor survival, its inhibition by GRIM-19 also demonstrates an antioncogenic effect exerted by biological therapeutics...
  17. ncbi Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
    Sizhi Paul Gao
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 117:3846-56. 2007
    ..Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment...
  18. ncbi IL-6 rescues the hyporesponsiveness of c-Rel deficient B cells independent of Bcl-xL, Mcl-1, and Bcl-2
    Joseph R Tumang
    Department of Medicine, Division of Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Cell Immunol 217:47-57. 2002
    ..Together, these data demonstrate that IL-6 enhances B cell responses by employing multiple survival factors...

Research Grants11

  1. Role of Stat3 in Breast Cancer Tumorigenesis
    Jacqueline Bromberg; Fiscal Year: 2005
    ..In addition, we will begin to characterize the potential regulators of Stat3 activation in these tissue specimens. ..
  2. Role of Stat3 in Breast Cancer Tumorigenesis
    Jacqueline F Bromberg; Fiscal Year: 2010
    ....